Posted by Ryan Terlecki, MD, FACS | Dec 2017
Dr. Ryan P. Terlecki presented “Prostate Physiology: The Most Diseased Organ in the Male Body” at the 26th Annual Perspectives in Urology: Point-Counterpoint , November 10, 2017 in Scottsdale, AZ How to cite: Terlecki, Ryan P. “Prostate Physiology: The Most Diseased Organ in the Male Body” November 10, 2017. Accessed Dec 2017. https://grandroundsinurology.com/prostate-physiology-diseased-organ Summary: Dr. Ryan P. Terlecki, MD, FACS, outlines prostate physiology and the prostate microbiome, explaining how both lend themselves to a cancer-prone or an infection-prone status, especially as men age. Prostate Physiology: The Most Diseased Organ in the Male Body Edited Transcript: I was glad to be assigned this...Read More
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?
Posted by Lawrence Karsh, MD | Nov 2017
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses what some of the challenges are for urologists treating metastatic castrate resistant prostate cancer patients. Interview produced by Prostatepedia Keywords: metastatic castrate resistant prostate cancer, learning curve, adverse events, therapies, clinical practice...Read More
Posted by Raoul S. Concepcion, MD | Nov 2017
Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising. Interview produced by Prostatepedia Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer Summary: In 2017, immunotherapy has been a popular approach for treating all tumor types. However, in this video, Dr. Concepcion explains specific recent advances in using immunotherapy for prostate cancer. He also discusses one of the toughest questions facing urologists today – can we combine immunotherapeutic agents with other treatments? Since the only FDA approved immunotherapy, Sipuleucel-T, or PROVENGE, won’t attack androgen receptors, can we combine...Read More